Ascendis Pharma A/S Reports First Quarter 2021 Financial Results


– Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021 –

Read more here:
Ascendis Pharma A/S Reports First Quarter 2021 Financial Results

Related Posts